Recruiting PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT04704921

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (ATMOSPHERE)

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

Sponsor: AbbVie

Conditions AMD CNV Choroidal Neovascularization Neovascular AMD Neovascular Age-related Macular Degeneration Wet AMD Wet Age-related Macular Degeneration nAMD wAMD

Interventions ABBV-RGX-314 Ranibizumab (LUCENTIS®)

Updated 14 times since 2021 Last updated: Feb 13, 2026 Started: Dec 29, 2020 Primary completion: Dec 31, 2026 Completion: Nov 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates AMD and CNV and is currently actively recruiting participants. AbbVie leads this study, which shows 14 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

14 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2/PHASE3
Sep 2025 — Feb 2026 [monthly]

Recruiting PHASE2/PHASE3
Feb 2025 — Sep 2025 [monthly]

Recruiting PHASE2/PHASE3
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3

▶ Show 9 earlier versions

May 2024 — Jul 2024 [monthly]

Recruiting PHASE2_PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE2_PHASE3
Jun 2023 — Apr 2024 [monthly]

Recruiting PHASE2_PHASE3
Mar 2023 — Jun 2023 [monthly]

Recruiting PHASE2_PHASE3
Oct 2022 — Mar 2023 [monthly]

Recruiting PHASE2_PHASE3
Jun 2022 — Oct 2022 [monthly]

Recruiting PHASE2_PHASE3
Oct 2021 — Jun 2022 [monthly]

Recruiting PHASE2_PHASE3
Jun 2021 — Oct 2021 [monthly]

Recruiting PHASE2_PHASE3
Feb 2021 — Jun 2021 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie
REGENXBIO Inc.

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Albuquerque, United States , Augusta, United States , Austin, United States , Baltimore, United States , Beaumont, United States , Bellaire, United States , Bellevue, United States , Beverly Hills, United States , Boston, United States and 70 more locations